Utilization of optical coherence tomography as a noninvasive, bedside imaging technique to identify residual nodular basal cell carcinoma at a well-healed and clinically unidentifiable biopsy site - 21/06/19
Key words : bedside imaging, biopsy site identification, dermatologic surgery, OCT, optical coherence tomography, skin cancer, wrong site surgery
Plan
Funding sources: None. |
|
Conflicts of interest: Mr Holmes is an employee and shareholder of Michelson Diagnostics Ltd, which manufacturers the optical coherence tomography equipment used in the study. Dr Geronemus is on the Medical Advisory Board for Allergan, Candela, Cearna, Cynosure, Cytrellis, Lutronics, and Soliton; an investigator for Allergan, ArchiMedus, Candela, Cynosure, Cytrellis, Endo Pharmaceuticals, Kerastem, Lutronic, Merz, Miramar, New York Stem Cell Foundation, Revance, Sciton, and Sienna Labs; and a stockholder of Cytrellis. Dr Feng and Dr Christman have no conflicts of interest to disclose. |
Vol 81 - N° 1
P. e9-e10 - juillet 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?